Expert Interviews

An expert spotlights how open data communication between payers and fertility clinics can drive collaboration expanding coverage for proven, successful treatments that crucially improve assisted reproductive outcomes when timely access barriers are eliminated through aligned medical policies.

Important takeaways for patients, payers, and providers are covered by expert faculty.

Robert Spiera, M.D., highlights the significance of the SAPHYR trial, presenting a nonsteroid option for patients with refractory polymyalgia rheumatica that addresses unmet needs, reduces long-term corticosteroid-related burdens and benefits healthcare providers, payers, and patients alike.

Thomas Crawford, MD, discusses exciting new findings from the pivotal NURTURE study.

Robert Spiera, M.D., discusses the criteria for determining the suitability of sarilumab in polymyalgia rheumatica patients, with a particular focus on indicators of steroid intolerance.

In his final thoughts, Dr. Chervenak provides recommendations for optimal patient outcomes by tailoring design of health benefits.

Longitudinal trends in hospitalization rates in patients with later-onset SMA (SMA) treated with nusinersen up to 4.5 years are discussed. Results from the CHERISH and SHINE studies are discussed.

Delving into the realm of refractory polymyalgia rheumatica, Robert Spiera, M.D., discusses the potential inclusion of sarilumab in revised guidelines. He addresses payer concerns regarding prior authorization while emphasizing the importance of ensuring appropriate patient access through evidence-based approaches.

Further discussion of the SHINE study explores characteristics unique to the trial's patient population.

Socioeconomic factors impacting patients seeking infertility treatment are highlighted.

Robert Spiera, M.D., highlights the impact of sustained remission on polymyalgia rheumatica treatment, emphasizing improvements in quality of life and steroid-related effects.

Robert Spiera, M.D., explores sarilumab’s impact on polymyalgia rheumatica, emphasizing reduced steroid use and enhanced quality of life.

A medical expert underscores the significance of infertility treatment coverage.

This study explores the background and rationale behind utilizing nusinersen for the treatment of Spinal Muscular Atrophy (SMA), shedding light on the critical need for the SHINE study. Delving into the characteristics of the patient population involved, the research aims to deepen our understanding of the therapeutic potential of nusinersen in addressing SMA, a debilitating genetic disorder.

Robert Spiera, M.D., reviews key patient characteristics from the study of sarilumab in refractory polymyalgia rheumatica.

Sean Tipton delivers an expert perspective on harnessing fertility benefits.

Dr. Chervenak evaluates access to care in the current health care system for patients seeking treatment in reproductive medicine.

Robert Spiera, M.D., discusses the SAPHYR trial, assessing sarilumab’s efficacy in treating refractory polymyalgia rheumatica.

A key opinion leader discusses trending and breakthrough treatment strategies for patients seeking infertility treatment.

Dana McCormick, R.Ph., and Robert Spiera, M.D., delve into the SAPHYR trial, discussing sarilumab’s role in managing polymyalgia rheumatica relapse during glucocorticoid tapers.

Joseph Chervenak, MD, MBA, begins a discussion surrounding innovative processes in reproductive medicine.

Drs. Owens and Rosmarin discuss payer and provider perspectives from the TRuE-V studies.

The limitations from the TRuE-V studies are analyzed.

By identifying patients with glaucoma who are socially vulnerable, clinicians might intervene sooner and prevent the worsening of visual impairment, he said.

Key adverse events from the TRuE-V studies are highlighted.

Dr. Rosmarin discusses the efficacy data from the TRuE-V long-term extension study.

A medical expert highlights a new FDA-approved medication as a key treatment in Demodex blepharitis.

The study design for the TRuE-V long-term extension study is discussed.

Therapies such as tee tree oil and other OTC agents are evaluated in the management of Demodex blepharitis.